(SXT) Sensient Technologies - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 4.814m USD | Total Return: 23.9% in 12m
Avg Turnover: 46.1M
EPS Trend: 73.5%
Qual. Beats: 1
Rev. Trend: 98.6%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Sensient Technologies Corporation (NYSE: SXT) is a global manufacturer of colors, flavors, and specialty ingredients serving the food, beverage, pharmaceutical, and personal care industries. The company operates through three primary segments: Flavors & Extracts, Color, and Asia Pacific. Its portfolio includes natural and synthetic coloring systems, flavor delivery technologies, and dehydrated agricultural ingredients such as garlic and onion.
Operating within the specialty chemicals sector, Sensient relies on a business model driven by high-value research and development to meet strict regulatory standards and shifting consumer preferences for natural ingredients. The industry is characterized by high barriers to entry due to complex formulation requirements and integrated supply chains for raw materials like essential oils and botanical extracts. For a deeper look at these fundamentals, consider reviewing the companys historical performance on ValueRay.
Headquartered in Milwaukee, Wisconsin, the firm maintains a global footprint with dedicated operations across the Pacific Rim and India. Beyond standardized ingredients, Sensient produces specialized technical colors for industrial applications and excipients for the nutraceutical market.
- Shift toward natural food colors drives global consumer demand and volume growth
- Raw material costs for agricultural ingredients impact flavor and extract margins
- Expansion into pharmaceutical and personal care markets diversifies revenue beyond food
- Currency fluctuations in Asia Pacific markets affect consolidated earnings and competitiveness
- Stricter global food safety regulations increase compliance costs and operational risks
| Net Income: 144.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.29 > 1.0 |
| NWC/Revenue: 54.23% < 20% (prev 49.17%; Δ 5.06% < -1%) |
| CFO/TA 0.05 > 3% & CFO 123.2m > Net Income 144.2m |
| Net Debt (729.2m) to EBITDA (281.9m): 2.59 < 3 |
| Current Ratio: 5.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.7m) vs 12m ago 0.48% < -2% |
| Gross Margin: 33.84% > 18% (prev 0.33%; Δ 3.35k% > 0.5%) |
| Asset Turnover: 75.59% > 50% (prev 74.78%; Δ 0.82% > 0%) |
| Interest Coverage Ratio: 7.31 > 6 (EBITDA TTM 281.9m / Interest Expense TTM 30.1m) |
| A: 0.39 (Total Current Assets 1.12b - Total Current Liabilities 223.7m) / Total Assets 2.29b |
| B: 0.82 (Retained Earnings 1.87b / Total Assets 2.29b) |
| C: 0.10 (EBIT TTM 220.3m / Avg Total Assets 2.19b) |
| D: 1.60 (Book Value of Equity 1.71b / Total Liabilities 1.07b) |
| Altman-Z'' = 7.60 = AAA |
| DSRI: 1.03 (Receivables 342.3m/315.0m, Revenue 1.66b/1.56b) |
| GMI: 0.97 (GM 33.84% / 32.74%) |
| AQI: 0.95 (AQ_t 0.27 / AQ_t-1 0.28) |
| SGI: 1.06 (Revenue 1.66b / 1.56b) |
| TATA: 0.01 (NI 144.2m - CFO 123.2m) / TA 2.29b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 113.09 with a total of 352,851 shares traded.
Over the past week, the price has changed by +0.45%,
over one month by +19.99%,
over three months by +25.00% and
over the past year by +23.94%.
Sensient Technologies has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SXT.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 133 | 17.6% |
P/E Forward = 22.7273
P/S = 2.9077
P/B = 3.9846
P/EG = 1.7352
Revenue TTM = 1.66b USD
EBIT TTM = 220.3m USD
EBITDA TTM = 281.9m USD
Long Term Debt = 767.6m USD (from longTermDebt, last quarter)
Short Term Debt = 232k USD (from shortTermDebt, last quarter)
Debt = 767.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 729.2m USD (calculated: Debt 767.8m - CCE 38.5m)
Enterprise Value = 5.54b USD (4.81b + Debt 767.8m - CCE 38.5m)
Interest Coverage Ratio = 7.31 (Ebit TTM 220.3m / Interest Expense TTM 30.1m)
EV/FCF = 253.2x (Enterprise Value 5.54b / FCF TTM 21.9m)
FCF Yield = 0.39% (FCF TTM 21.9m / Enterprise Value 5.54b)
FCF Margin = 1.32% (FCF TTM 21.9m / Revenue TTM 1.66b)
Net Margin = 8.71% (Net Income TTM 144.2m / Revenue TTM 1.66b)
Gross Margin = 33.84% ((Revenue TTM 1.66b - Cost of Revenue TTM 1.10b) / Revenue TTM)
Gross Margin QoQ = 35.03% (prev 31.35%)
Tobins Q-Ratio = 2.42 (Enterprise Value 5.54b / Total Assets 2.29b)
Interest Expense / Debt = 3.93% (Interest Expense 30.1m / Debt 767.8m)
Taxrate = 24.91% (14.7m / 58.8m)
NOPAT = 165.4m (EBIT 220.3m * (1 - 24.91%))
Current Ratio = 5.01 (Total Current Assets 1.12b / Total Current Liabilities 223.7m)
Debt / Equity = 0.63 (Debt 767.8m / totalStockholderEquity, last quarter 1.22b)
Debt / EBITDA = 2.59 (Net Debt 729.2m / EBITDA 281.9m)
Debt / FCF = 33.31 (Net Debt 729.2m / FCF TTM 21.9m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.58% (Net Income 144.2m / Total Assets 2.29b)
RoE = 12.14% (Net Income TTM 144.2m / Total Stockholder Equity 1.19b)
RoCE = 11.27% (EBIT 220.3m / Capital Employed (Equity 1.19b + L.T.Debt 767.6m))
RoIC = 8.01% (NOPAT 165.4m / Invested Capital 2.06b)
WACC = 7.18% (E(4.81b)/V(5.58b) * Re(7.86%) + D(767.8m)/V(5.58b) * Rd(3.93%) * (1-Tc(0.25)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 0.65%
[DCF] Terminal Value 73.10% ; FCFF base≈40.3m ; Y1≈35.4m ; Y5≈28.6m
[DCF] Fair Price = N/A (negative equity: EV 458.8m - Net Debt 729.2m = -270.5m; debt exceeds intrinsic value)
EPS Correlation: 73.51 | EPS CAGR: 7.24% | SUE: 1.33 | # QB: 1
Revenue Correlation: 98.57 | Revenue CAGR: 4.97% | SUE: 3.73 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=+4.70% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.03 | Chg30d=+2.53% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=3.93 | Chg30d=+5.59% | Revisions=+43% | GrowthEPS=+12.9% | GrowthRev=+10.3%
EPS next Year (2027-12-31): EPS=4.74 | Chg30d=+6.28% | Revisions=+43% | GrowthEPS=+20.7% | GrowthRev=+10.9%
[Analyst] Revisions Ratio: +43%